Predictors of Severe Exacerbations, Poor Asthma Control, and β-Agonist Overuse for Patients with Asthma

Journal of Allergy and Clinical Immunology: In Practice

Volumn 2, Issue 6, 2014, Pages 751-758.e1

  Patel, Mitesh ^a,b,c   Pilcher, Janine ^a,b   Reddel, Helen K ^d   Qi, Victoria ^e   Mackey, Bill ^e   Tranquilino, Tyronne ^e   Shaw, Dominick ^c   Black, Peter ^f   Weatherall, Mark ^b,g   Beasley, Richard ^a,b,g  

^a MEDICAL RESEARCH INSTITUTE OF NEW ZEALAND   (New Zealand)

^b CAPITAL AND COAST DISTRICT HEALTH BOARD   (New Zealand)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d UNIVERSITY OF SYDNEY   (Australia)

^e Henderson Medical Centre   (New Zealand)

^f UNIVERSITY OF AUCKLAND   (New Zealand)

^g UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Asthma; Electronic monitoring; Predictors; Risk; agonist

Indexed keywords

BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; SALBUTAMOL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; DRUG COMBINATION; ETHANOLAMINE DERIVATIVE; FORMOTEROL; GLUCOCORTICOID;

ADULT; ADVERSE OUTCOME; AGE; ARTICLE; ASTHMA; ASTHMA CONTROL QUESTIONNAIRE; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MONITORING; DRUG USE; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; MAJOR CLINICAL STUDY; MALE; MAORI (PEOPLE); METERED DOSE INHALER; MULTICENTER STUDY; OPEN STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SEX; CLINICAL TRIAL; DISEASE COURSE; DRUG COMBINATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW ZEALAND; PATHOPHYSIOLOGY; PROSPECTIVE STUDY; RISK; RISK FACTOR; SEVERITY OF ILLNESS INDEX; TIME; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ALBUTEROL; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; DISEASE PROGRESSION; DRUG COMBINATIONS; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; LUNG; MALE; METERED DOSE INHALERS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEW ZEALAND; ODDS RATIO; PROSPECTIVE STUDIES; QUESTIONNAIRES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84923226763     PISSN: 22132198     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaip.2014.06.001     Document Type: Article

References (42)

1. Global Strategy for Asthma Management and Prevention, Global Initiative for Asthma (GINA) 2012. Available from: . Accessed March 18, 2014. http://www.ginasthma.org.
2. National Asthma Education and Prevention Program Expert Panel Report 3: guidelines for the diagnosis and management of asthma 2007, National Heart, Lung, and Blood Institute, Available from:, Accessed March 18, 2014. https://www.nhlbi.nih.gov/guidelines/asthma/index.htm.
3. Bateman E.D., Reddel H.K., Eriksson G., Peterson S., Ostlund O., Sears M.R., et al. Overall asthma control: the relationship between current control and future risk. JAllergy Clin Immunol 2010, 125:600-608.
4. Schatz M., Zeiger R.S., Yang S.J., Chen W., Crawford W., Sajjan S., et al. The relationship of asthma impairment determined by psychometric tools to future asthma exacerbations. Chest 2012, 141:66-72.
5. Reddel H.K., Taylor D.R., Bateman E.D., Boulet L.P., Boushey H.A., Busse W.W., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009, 180:59-99.
6. Chipps B.E., Zeiger R.S., Borish L., Wenzel S.E., Yegin A., Hayden M.L., et al. Key findings and clinical implications from The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. JAllergy Clin Immunol 2012, 130:332-342.
7. Kitch B.T., Paltiel A.D., Kuntz K.M., Dockery D.W., Schouten J.P., Weiss S.T., et al. Asingle measure of FEV1 is associated with risk of asthma attacks in long-term follow-up. Chest 2004, 126:1875-1882.
8. Meltzer E.O., Busse W.W., Wenzel S.E., Belozeroff V., Weng H.H., Feng J., et al. Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation. JAllergy Clin Immunol 2011, 127:167-172.
9. McCoy K., Shade D.M., Irvin C.G., Mastronarde J.G., Hanania N.A., Castro M., et al. Predicting episodes of poor asthma control in treated patients with asthma. JAllergy Clin Immunol 2006, 118:1226-1233.
10. Tattersfield A.E., Postma D.S., Barnes P.J., Svensson K., Bauer C.A., O'Byrne P.M., et al. Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group. Am J Respir Crit Care Med 1999, 160:594-599.
11. O'Connor R.D., Bleecker E.R., Long A., Tashkin D., Peters S., Klingman D., et al. Subacute lack of asthma control and acute asthma exacerbation history as predictors of subsequent acute asthma exacerbations: evidence from managed care data. JAsthma 2010, 47:422-428.
12. Schatz M., Zeiger R.S., Vollmer W.M., Mosen D., Cook E.F. Determinants of future long-term asthma control. JAllergy Clin Immunol 2006, 118:1048-1053.
13. Ko F.W., Hui D.S., Leung T.F., Chu H.Y., Wong G.W., Tung A.H., et al. Evaluation of the asthma control test: a reliable determinant of disease stability and a predictor of future exacerbations. Respirology 2012, 17:370-378.
14. Nathan R.A., Sorkness C.A., Kosinski M., Schatz M., Li J.T., Marcus P., et al. Development of the asthma control test: a survey for assessing asthma control. JAllergy Clin Immunol 2004, 113:59-65.
15. Spitzer W., Suissa S., Ernst P., Horwitz R., Habbick B., Cockcroft D., et al. The use of beta-agonists and the risk of death and near death from asthma. NEngl J Med 1992, 326:501-506.
16. Suissa S., Blais L., Ernst P. Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 1994, 7:1602-1609.
17. Patel M., Pilcher J., Pritchard A., Perrin K., Travers J., Shaw D., et al. Efficacy and safety of maintenance and reliever combination budesonide-formoterol inhaler in patients with asthma at risk of severe exacerbations: a randomised controlled trial. Lancet Respir Med 2013, 1:32-42.
18. Symbicort SMART Asthma Action Plan. National Asthma Council Australia. Available from: . Accessed March 18, 2014. http://www.nationalasthma.org.au/health-professionals/tools-for-primary-care/asthma-action-plans/asthma-action-plan-library.
19. Juniper E.F., O'Byrne P.M., Guyatt G.H., Ferrie P.J., King D.R. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999, 14:902-907.
20. Juniper E.F., Svensson K., Mork A.C., Stahl E. Measurement properties and interpretation of three shortened versions of the asthma control questionnaire. Respir Med 2005, 99:553-558.
21. Miller M.R., Hankinson J., Brusasco V., Burgos F., Casaburi R., Coates A., et al. Standardisation of spirometry. Eur Respir J 2005, 26:319-338.
22. Burgess S.W., Wilson S.S., Cooper D.M., Sly P.D., Devadason S.G. In vitro evaluation of an asthma dosing device: the smart-inhaler. Respir Med 2006, 100:841-845.
23. Patel M., Pilcher J., Chan A., Perrin K., Black P., Beasley R. Six-month in vitro validation of a metered-dose inhaler electronic monitoring device: implications for asthma clinical trial use. JAllergy Clin Immunol 2012, 130:1420-1422.
24. Patel M., Pilcher J., Travers J., Perrin K., Shaw D., Black P., et al. Use of metered-dose inhaler electronic monitoring in a real-world asthma randomized controlled trial. JAllergy Clin Immunol Pract 2013, 1:83-91.
25. Juniper E.F., Bousquet J., Abetz L., Bateman E.D. Identifying 'well-controlled' and 'not well-controlled' asthma using the Asthma Control Questionnaire. Respir Med 2006, 100:616-621.
26. Holt S., Masoli M., Beasley R. The use of the self-management plan system of care in adult asthma. Prim Care Respir J 2004, 13:19-27.
27. Balanag V.M., Yunus F., Yang P.C., Jorup C. Efficacy and safety of budesonide/formoterol compared with salbutamol in the treatment of acute asthma. Pulm Pharmacol Ther 2006, 19:139-147.
28. Rubinfeld A.R., Scicchitano R., Hunt A., Thompson P.J., Van Nooten A., Selroos O. Formoterol Turbuhaler as reliever medication in patients with acute asthma. Eur Respir J 2006, 27:735-741.
29. Adams R.J., Smith B.J., Ruffin R.E. Factors associated with hospital admissions and repeat emergency department visits for adults with asthma. Thorax 2000, 55:566-573.
30. Zeiger R.S., Yegin A., Simons F.E., Haselkorn T., Rasouliyan L., Szefler S.J., et al. Evaluation of the National Heart, Lung, and Blood Institute guidelines impairment domain for classifying asthma control and predicting asthma exacerbations. Ann Allergy Asthma Immunol 2012, 108:81-87.
31. O'Byrne P.M., Bisgaard H., Godard P.P., Pistolesi M., Palmqvist M., Zhu Y., et al. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 2005, 171:129-136.
32. Rabe K.F., Atienza T., Magyar P., Larsson P., Jorup C., Lalloo U.G. Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 2006, 368:744-753.
33. Lee J.H., Haselkorn T., Chipps B.E., Miller D.P., Wenzel S.E. Gender differences in IgE-mediated allergic asthma in the epidemiology and natural history of asthma: Outcomes and Treatment Regimens (TENOR) study. JAsthma 2006, 43:179-184.
34. Schatz M., Camargo C.A. The relationship of sex to asthma prevalence, health care utilization, and medications in a large managed care organization. Ann Allergy Asthma Immunol 2003, 91:553-558.
35. Abramson M.J., Bailey M.J., Couper F.J., Driver J.S., Drummer O.H., Forbes A.B., et al. Are asthma medications and management related to deaths from asthma?. Am J Respir Crit Care Med 2001, 163:12-18.
36. Fraser P.M., Speizer F.E., Waters S.D., Doll R., Mann N.M. The circumstances preceding death from asthma in young people in 1968 to 1969. Br J Dis Chest 1971, 65:71-84.
37. Crane J., Lewis S., Slater T., Crossland L., Robson B., D'Souza W., et al. The self reported prevalence of asthma symptoms amongst adult New Zealanders. NZ Med J 1994, 107:417-421.
38. Ellison-Loschmann L., Cheng S., Pearce N. Time trends and seasonal patterns of asthma deaths and hospitalisations among Maori and non-Maori. NZ Med J 2002, 115:6-9.
39. Jenkins C.R., Chang A.B., Poulos L.M., Marks G.B. Asthma in indigenous Australians: so much yet to do for Indigenous lung health. Med J Aust 2009, 190:530-531.
40. Netuveli G., Hurwitz B., Levy M., Fletcher M., Barnes G., Durham S.R., et al. Ethnic variations in UK asthma frequency, morbidity, and health-service use: a systematic review and meta-analysis. Lancet 2005, 365:312-317.
41. Gorman B.K., Chu M. Racial and ethnic differences in adult asthma prevalence, problems, and medical care. Ethn Health 2009, 14:527-552.
42. Ospina M.B., Voaklander D.C., Stickland M.K., King M., Senthilselvan A., Rowe B.H. Prevalence of asthma and chronic obstructive pulmonary disease in Aboriginal and non-Aboriginal populations: a systematic review and meta-analysis of epidemiological studies. Can Respir J 2012, 19:355-360.